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Abstract
Background: The diagnosis of breast cancer requires a compli-
cated series of diagnostic exams. The present study addressed the
delay of patients who used publicly and privately financed diag-
nostic services. Non-governmental organizations (NGOs) donated
diagnostic mammograms and biopsies.
Design and Methods: Data from 304 patients were obtained
from two Brazilian referral centres. In one referral centre (FAP),
diagnostic mammography, clinic-histopathological exam and
immunohistochemistry were outsourced, whereas in the other cen-
tre (HNL), these services were integrated. Cox regression,
Kaplan-Meier analysis and non-parametric tests were used to
compare variables and time intervals.
Results: If diagnostic mammography was financed privately
and covered by private health insurance, the likelihood of a delay
of >90 days between the first medical visit and the initiation of
treatment decreased 2.15-fold (95%CI: 1.06- 4.36; p=0.033) and
4.44-fold (95%CI: 1.58-12.46; p=0.004), respectively. If the clin-
ic-histopathological exam was outsourced (FAP) and publicly or
privately financed, the median time between diagnostic mammog-
raphy and the diagnostic result was 53 and 65 days in the integrat-
ed (HNL) and outsourced public system, compared to 29 days in
the outsourced private system (p<0.050). The median time
between the first medical visit and the diagnostic results of
patients who were supported by NGOs, who financed their diag-
nostic services privately, and who used exclusively public diag-
nostic services was, respectively, 28.0, 48.5 and 77.5 days
(p<0.050).
Conclusion: Patients who used privately financed health ser-
vices had shorter delays. Compared to outsourcing, the integration
of the publicly financed clinic- histopathological exam diminished
the delay. The support of patients by NGOs accelerated patient
flow.
Introduction
Breast cancer is the most common cancer worldwide, and
between 2005 and 2015, the incidence of disease increased by
33% from 1.7 to 2.4 million cases worldwide.1 Incidence and mor-
tality rates remained stable or even declined in developed coun-
tries, whereas they increased in developing countries mainly due
to prolonged life expectancy and changing lifestyle and reproduc-
tive patterns.2 Of all regions in the world, Latin America and the
Caribbean had the highest-increasing mortality trend between
1990 and 2015, with a slope of 1.48 per 100,000 women.1
Brazil has approximately 209 million inhabitants, making it
the largest Latin American country, and breast cancer currently
contributes to 29.5% of all neoplasms among women.3 The inci-
dence of disease has developed differentially in distinct regions of
the country: in the South, Southeast and Centre-West regions,
which also include the two largest urban centres of the country,
namely, São Paulo and Rio de Janeiro, the incidence has stabilized
over the last ten years.3,4 In contrast, in the Northeast region, the
incidence of breast cancer has increased between 2005 and 2018
from 27.23 to 63.98 new cases per 100,000 women.3,4
The diagnosis and treatment of breast cancer is complex and
requires a series of diagnostic and therapeutic procedures. These
successive diagnostic and therapeutic steps require time and can
lead to delays in the time to treatment initiation (TTI). Long wait-
ing times for diagnostic procedures, poor disease management,
barriers to access and a high number of services used before treat-
ment initiation were often identified as causal factors of TTI.5,6
Furthermore, low income, low educational level, no private health
insurance, poor communication and ethnic origin can hinder the
orientation of patients within the health system and negatively
influence the speed of treatment decisions by physicians.5
Additionally, the misinterpretation of symptoms by physicians can
be associated with the TTI.7
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Significance for public health
In many developing countries the incidence of breast cancer is increasing due to changing lifestyles and longer life expectancies. In Brazil, like in many other
developing countries, this increase is characterized by high mortality to incidence ratios. The complex diagnostic procedures of breast cancer can lead to time
delays from diagnosis to start of treatment. Previous Brazilian studies compared the time delays of diagnostic services and treatment between public and private
health service centres. The present Brazilian study is the first one that compared treatment delay between two public referral centres of breast cancer treatment,
one with integrated and the other one with outsourced diagnostic services. Results argue in favour of the integration of diagnostic services into the referral
centre, instead of outsourcing them. The study also documents the successful work of the two Brazilian non- governmental organizations “Mulheres de Peito”
and “Americas Amigas” that donate biopsies and diagnostic mammographies to low-income women.










Delays in the TTI were associated with advanced stage (stages
III and IV) of disease and poor prognosis.6,8,9 A recent study based
on data from more than 1.3 million cases of breast cancer from the
National Cancer Database of the United States showed that delays
in the TTI increased the mortality risk of stage I and stage II breast
cancer by 1.8%, respectively, or 1.2% per week.10 Delays in the
TTI of breast cancer are a major problem in low- and middle-
income countries, leading to high incidence-mortality rates.6
In Brazil, a high number of studies performed in the South,
Southeast and Centre-West regions of the country have addressed
causal factors of TTI.11-22 Some other studies have been performed
in the Northeast region.23-25 Few studies have compared the TTI of
breast cancer between public and private health services.21 One
factor that hampers direct comparison between private and public
health services is that many breast cancer patients who receive
treatment in a public health service centre also receive private ser-
vices.26,27 Approximately 25% of the Brazilian population has
access to private health services financed by individual health
insurance.26,27 Additionally, each service can be paid for directly
by a private individual. The Brazilian public “Sistema Único de
Saúde (SUS)” provides access to health facilities for all Brazilians,
regardless of their income. This means that in the case of disease,
patients have the option to combine self-financed private and free
public health services for diagnosis and treatment. In addition, the
SUS is a decentralized system that allows cooperation between the
public and private health sectors, affording the possibility of con-
tracts between municipal governments and private health care
providers.27 In the case of cancer diagnosis, this means that there
are public referral centres for treatment that offer all diagnostic ser-
vices within a hospital, whereas other centres outsource these diag-
nostic services in part or in full.
The present study addressed the TTI of patients from two refer-
ral centres of breast cancer treatment in north-eastern Brazil. In the
hospital Fundação Assistencial da Paraíba (FAP), diagnostic
mammography, clinic-histopathological exam, and immunohisto-
chemistry were outsourced, whereas in the Hospital Napoleão
Laureano (HNL), these diagnostic services were integrated. First,
we examined which socio- economic variables were associated
with a longer TTI. Second, specific time intervals from first medi-
cal visit to treatment initiation were compared between both refer-
ral centres. Third, the time intervals of both referral centres were
compared among patient groups who financed one or more health
services on their own during patient flow and among patients who
received all diagnostic services within the public health system.
Fourth, the effect of integration and outsourcing of a clinical
histopathological exam on patient flow was analysed. Fifth, the
impact of biopsies and diagnostic mammograms donated by two
non-governmental organizations (NGOs) on the TTI was analysed.
Design and Methods
Study population
The present study was performed in João Pessoa and Campina
Grande, two urban centres in the Northeast region of Brazil. João
Pessoa, the capital of the state of Paraíba, has approximately
800,000 inhabitants and is located on the coast.28 Campina Grande,
with approximately 400,000 inhabitants, is the second-most popu-
lated urban centre in Paraíba and is located approximately 120 km
away from the capital in the interior of the state.28 Paraíba has a
mixed-ethnic population of indigenous, African and European
ancestry.
Patients of two different referral centres
Patient data were obtained from two Brazilian cancer treatment
referral centres: the HNL in João Pessoa and the FAP hospital in
Campina Grande. Both referral centres together treat more than
90% of all breast cancer patients in the state of Paraíba. Patients
come from as far as 400 km away to the HNL and FAP. The HNL
has an integrated pathology section. Therefore, anatomic-
histopathological and immunohistochemical exams can be per-
formed within the referral centre. Furthermore, diagnostic mam-
mography can also be performed in the referral centre. The FAP, by
contrast, does not have a pathology section, and their patients did
not undergo diagnostic mammography at the referral centre. In the
case of the FAP, diagnostic mammography and clinic-histopatho-
logical and immunohistochemical exams were financed by the
public SUS or were financed privately but were always performed
by private laboratories and medical centres in Campina Grande.
Participating women
All data were collected between October 2016 and March
2019. A total of 304 women participated in the study, of which 107
(35.2%) and 197 (64.8%) were patients from the FAP and HNL,
respectively. Only patients with invasive tumours who received
treatment in one of the two referral centres (FAP or HNL) were
included in the study. Furthermore, only patients who received a
diagnosis of disease within the last three years from the beginning
of data collection were included in the study. The recruitment of
patients was initiated with an interview (see below).
In 199 (65.5%) cases, treatment was initiated during the time
interval of data collection. In 105 (34.5%) cases, treatment was ini-
tiated before the data collection began. Patients with recurring dis-
ease and patients with cognitive problems were excluded from the
study.
Data sampling from medical records
Authors of the study extracted data of medical records.
Clinical and histopathological data were obtained from medical
records in the medical archives of both hospitals. The following
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Figure 1. A schematic representation of patient flow and the
analysed time intervals. Following time intervals are shown from
the bottom to the top: First medical visit-> treatment initiation;
First medical visit-> hospital admission; First medical visit->
diagnostic result; Diagnostic result-> treatment initiation; Result
of diagnostic mammography-> treatment initiation; Result of
diagnostic mammography-> hospital admission; Result of diag-
nostic mammography-> diagnostic result.









data were also obtained from medical records: date of each diag-
nostic service before and after hospital admission; date of hospital
admission and treatment initiation; public or private health care
service used at first medical visit; date of first medical visit; type
of health care service used at first medical visit; private or public
coverage of costs of diagnostic services, including mammography,
ultrasonography, clinical breast examination and biopsy; and type
of first treatment in the FAP or HNL.
The date of the first medical visit was defined based on reason
for attendance; we included consultations for symptoms of breast
cancer or screen-detected tumours. Of all 304 patients, 272
(90.5%) sought medical help because of symptoms, whereas in 32
(9.5%) cases the tumour was detected by mammography screen-
ing. The diagnostic result was defined as the date when the result
of the clinical-histopathological exam was obtained. Treatment ini-
tiation was defined as the date of the first therapeutic treatment,
including surgery, chemotherapy and radiotherapy.
If the date of the usage of a particular medical and/or diagnos-
tic service was not documented in the medical record, the corre-
sponding patient was excluded from the analysis of the time inter-
val that included this service as a starting point or endpoint of a
defined time interval. The data of medical records in both referral
centres were not digitalized and were incomplete in many cases.
Therefore, in general, for each analysed time-interval, only the
dates of a portion of all 304 patients were available, which explains
the heterogeneity of the numbers of patients within identical
patient groups in different time intervals. Figure 1 is a schematic
representation of patient flow and analysed time intervals.
Interview of women
To obtain information about socio-demographic characteristics
and medical visits, all patients in this study were interviewed. The
interviews included questions referring to the following variables:
civil state; education level; occupation status; income; health
insurance status; first discovery of disease symptoms; and health
care services used before breast cancer diagnosis. A structured
questionnaire was administered to patients within the chemothera-
py and radiotherapy units of both hospitals. A similar questionnaire
has been established and used in previous studies.29 All interviews
were performed by one of the authors. The selection of patients for
interviews always occurred by direct face-to-face contact and in a
stochastic manner. All patients during a determined chemotherapy
and radiotherapy session were interviewed. Breast cancer patients
who were never present in the chemotherapy or radiotherapy units
during interviews were excluded from the study. Educational level
was defined as follows: Having no schooling was defined as “no
formal schooling”. The basic education level was defined as ≤8
years of basic school education. The middle education level was
defined as >8 years of school education. Minimum wage and its
multiples were used to characterize income. This is a popular and
well-known method used to define economic level among low-
and middle-class subjects.30 Minimum wage or less was defined as
“low” income, whereas incomes equivalent to two and three times
the minimum wage were defined as “basic” and “middle” income,
respectively. An income of four times the minimum wage was
defined as “high” income. The minimum wage in 2018 was R$
954.00/month (US$ 281.60/month; 1st January 2018). Women
were asked about quality of health care accessibility and the types,
as well as the frequency, of health service use before and after the
diagnosis of their disease. Additionally, women were asked about
their adherence to the mammography- screening programme. Of
all 304 women, 123 (40.5%) reported undergoing regular mam-
mography.
Organizations that donated diagnostic mammograms
and biopsies
The two NGOs (Mulheres de Peito in Campina Grande and
Amigos do Peito in João Pessoa), or, respectively, “Women of the
breast” (http://mulheresdepeito.com) and “Friends of the breast”
(http://amigosdopeitojampa.blogspot.com/p/o-grupo-amigos- do-
peito.htm), have been in operation since 2016 and 2006, respec-
tively, in the state of Paraíba. In the present study, both NGOs paid
for biopsies and breast examinations by mastologists. Furthermore,
they mediated direct contact with medical staff and diagnostic lab-
oratories. The work and donations of the NGOs were financed by
private initiatives and by the sales of a doll called Boneca Maria,
which is offered throughout the year but primarily during the pub-
lic mammography screening campaign in October (October Rosa).
With the cash receipts from the doll sales, the Mulheres de Peito
recently started to pay for mammography services as well.
The third NGO, called Américas Amigas (https://americasami-
gas.org.br/), was founded in 2009 and is active in 12 Brazilian
states. The group donates preventive and diagnostic mammogra-
phy and supports the education of specialized mammography staff.
In the present study, Américas Amigas donated mammography ser-
vices as well as needles for biopsies. In 2017, Mulheres de Peito
donated 400 mammograms in cooperation with the Américas
Amigas, who provided financial resources. In 2018, Américas
Amigas continued to donate mammograms for women in Campina
Grande. Private initiatives and company foundations support the
work of Américas Amigas. In April 2018, they received the certifi-
cates ONG Transparente and the Selo Doar for administrative and
financial transparency. In the present study, 30 women received
help from one of the NGOs.
Statistical analysis
Data were tabulated in Excel® software (version 10;
MICROSOFT, 2010). Cox regression analysis was performed with
R software (version 3.4.3; R Core Team, 2017) using the Therneau
T package (version 2.38; R Core Team, 2015). Univariate Cox
regression analysis was performed to identify significant variables
using the Wald test. Significant variables of univariate regression
analysis were used for stepwise Cox regression modelling with
multiple adjusted variables applying the criterion of Akaike. The
fit of the final model was tested using the Wald test.
Student’s t-tests, Pearson’s chi-square (χ2) test, non- paramet-
ric tests and Kaplan-Meier analysis were performed with SPSS
STATISTICS™ software (SPPS; IBM company; version 24).
Mean, median values and 75th percentiles were calculated to com-
pare total time intervals between groups without censoring data
using Student’s t-test and non- parametric tests. The fit of Kaplan-
Meier analysis was tested using the Breslow (Generalized
Wilcoxon)- test and Log Rank (Mantel-Cox)-test.
Results
Socio-economic and clinical characteristics
The mean age of all 304 patients was 54.56 (s=11.92) years,
and 108 (35.53%) of them were under 50 years old (Table 1).
Patients from the HNL and FAP were characterized by several dif-
ferences. Of all patients, 26 (24.5%) and 74 (37.6%) patients from
the FAP and HNL were employed (p=0.020; Table 1). In the HNL,
82 (56.59%) patients had grade III tumours compared to 29
(29.29%) in the FAP (p=0.010; Table 1). Metastases were detected
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in 34 (37.36%) patients in the HNL and in 19 (20.21%) patients in
the FAP (p=0.010; Table 1). All together, 46 (48.9%) and 56
(61.6%) patients of the FAP and HNL presented at an advanced
stage (III, IV) of disease (p=0.077; Table 1). Mammography
screening led to tumour detection in 6 (5.6%) and 26 (13.2%) cases
in the FAP and HNL (p=0.000; Table 1), respectively.
Patient-level characteristics associated with prolonged TTI
To identify variables that were associated with prolonged TTI,
the time interval of 90 days between the first medical consultation
and treatment initiation was compared in univariate analysis
among patients in different categories of socio-economic and clin-
ical characteristics (Table 2). Patients with middle education level,
respectively income, had a 1.93 (95%CI: 1.06-3.52) and 1.95- fold
(95%CI: 1.15-3.30) increased chance of prompt TTI compared to
those ones with basic education and income (p=0.030 and
p=0.012; Table 2). Women were asked which types of health ser-
vices and providers they used before the diagnosis of their disease
and at the initiation of patient flow: women who used public and
private health care services or who used only private services had,
respectively a 1.88-fold (95%CI: 1.09-3.23) or a 2.57-fold
(95%CI: 1.00- 6.63) increased chance of prompt TTI compared to
women who used exclusively public services (p=0.021 and
p=0.049, respectively; Table 2). Women who started patient flow
in a primary service had a 3.85-fold (HR=0.26; 95%CI: 1.83-
14.80) increased chance of delay compared to those who started
patient flow with a diagnostic service (p<0.001 for both; Table 2).
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Table 1. Socio-economic and clinical characteristics of the 304 patients from the FAP (n=107) and HNL (n=197) referral centres.
                                                    FAP                                       HNL                                      Total                                                    p*
Age
      Mean (years)                           54.6 (s= 11.92)                               54.6 (s= 11.71)                               54.6 (s= 12.06)                                                         0.100
                                                                   n (%)                                                n (%)                                                n (%)                                                                      
      20- 29 years                                           0                                                  1 (0.5%)                                           1 (0.3%)                                                               0.910
      30- 39 years                                     9 (8.4%)                                         21 (10.6%)                                        30 (9.9%)                                                                  
      40- 49 years                                  26 (24.3%)                                       51 (25.9%)                                       77 (25.3%)                                                                 
      50- 59 years                                  37 (34.6%)                                       61 (30.9%)                                       98 (32.2%)                                                                 
      60- 69 years                                  24 (22.4%)                                       38 (19.3%)                                       62 (20.4%)                                                                 
      ≥70 years                                      11 (10.3%)                                       25 (12.8%)                                       36 (11.9%)                                                                 
Living place
      Urban centre                               35 (32.7%)                                       85 (43.1%)                                      120 (39.5%)                                                            0.090
      Rural region                                 72 (67.3%)                                      112 (56.9%)                                     184 (60.5%)                                                                
Marital status
      In a relationship                          62 (57.9%)                                      104 (52.8%)                                     166 (54.6%)                                                            0.401
      Single                                             45 (42.1%)                                       93 (47.2%)                                      138 (45.4%)                                                                
Education level
      No formal schooling                     7 (6.5%)                                          14 (7.1%)                                         21 (6.9%)                                                              0.780
      Basic                                              64 (59.8%)                                       77 (39.1%)                                      141 (46.4%)                                                                
      Middle                                           36 (33.6%)                                      106 (53.8%)                                     142 (46.7%)                                                                
Occupation status
      Employed                                      26 (24.5%)                                       74 (37.6%)                                      100 (32.9%)                                                            0.020
      Unemployed                                 81 (75.7%)                                      123 (62.4%)                                     204 (67.1%)                                                                
Income
      Low                                                   5 (4.7%)                                           1 (0.5%)                                           6 (2.0%)                                                               0.020
      Basic                                              65 (60.7%)                                      131 (66.5%)                                     196 (64.5%)                                                                
      Middle                                           25 (23.4%)                                       54 (27.4%)                                       79 (26.0%)                                                                 
      High                                                12 (11.2%)                                        11 (5.6%)                                         23 (7.5%)                                                                  
Private Health Insurance
      Yes                                                  18 (16.8%)                                        19 (9.6%)                                        37 (12.2%)                                                             0.100
      No                                                   89 (83.2%)                                      178 (90.4%)                                     267 (87.8%)                                                                
Histological grade
      I                                                         2 (2.0%)                                           4 (2.3%)                                           6 (2.2%)                                                               0.010
      II                                                     68 (68.7%)                                       90 (90.9%)                                      158 (57.5%)                                                                
      III                                                    29 (29.3%)                                       82 (82.8%)                                      111 (40.3%)                                                                
      Missing                                                   8                                                        21                                                       29                                                                         
Metastases
      Yes                                                  19 (20.2%)                                       34 (37.4%)                                       53 (28.6%)                                                             0.010
      No                                                   75 (79.8%)                                       57 (62.3%)                                      132 (71.5%)                                                                
      Missing                                                  13                                                      106                                                     119                                                                        
TNM
      I                                                       19 (20.2%)                                       15 (16.5%)                                       34 (18.4%)                                                             0.077
      II                                                     29 (30.9%)                                       20 (21.9%)                                       49 (26.5%)                                                                 
      III                                                    27 (28.7%)                                       22 (24.2%)                                       49 (26.5%)                                                                 
      IV                                                    19 (20.2%)                                       34 (37.4%)                                       53 (28.6%)                                                                 
Missing                                                        13                                                      106                                                     119                                                                        










Financing of diagnostic mammography by the public health sys-
tem increased the chance of delay 2.38-fold (HR= 0.42; 95%CI:
0.23 – 0.78), compared to direct private payment (p<0.001; Table
2). Similarly, patients who privately covered the costs of biopsy
had a 1.80-fold (95%CI: 1.01-3.19) increased chance of prompt
TTI compared to those whose costs were covered by the public
health system (p=0.045; Table 2). Of all 304 patients, 10 (3.3%)
covered the costs of most diagnostic services by private health
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Table 2. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) of single variables are shown in univariate Cox regression analy-
sis. The HR was calculated as the likelihood of hospital treatment initiation within 90 days after the first medical consultation (n= 76).
                                                                                                   Missing                N (%)                  Median               HR (CI 95%)          p*
Marital status
     In a relationship                                                                                                     1                         92 (52.6%)                        118.0                                 Ref
     Single                                                                                                                                                    83 (47.4%)                        116.0                      1.39 (0.85-2.29)          0.192
Education level
     Basic                                                                                                                         -                         138 (78.4%)                       120.5                                 Ref
     No formal schooling                                                                                                                           13 (7.4%)                         180.0                       0.37(0.09-1.56)           0.179
     Middle                                                                                                                                                25 (14.2%)                        75.0                       1.93 (1.06-3.52)           0.030
Occupation status
     Unemployed                                                                                                             -                         119 (67.6%)                       122.0                                 Ref
     Employed                                                                                                                                             57 (32.4%)                        102.0                    1.54 (-0.07 - 0.94)        0.090
Income
     Basic                                                                                                                          2                        111 (63.8%)                        122                                   Ref
     Low                                                                                                                                                         6 (3.4%)                           196                      1.20 (0.28 – 5.00)         0.801
     Middle                                                                                                                                                  47 (27.0%)                          89                         1.95 (1.15-3.30)           0.012
     High                                                                                                                                                        10 (5.8%)                          118                        1.09 (0.33-3.57)           0.880
Private health insurance
     No                                                                                                                               -                         156 (88.6%)                       118.5                                 Ref.
     Yes                                                                                                                                                        20 (11.4%)                        107.5                      1.33 (0.65-2.70)           0.439
Histological grade
     II                                                                                                                                 7                         94 (55.6%)                        110.0                                 Ref
     III                                                                                                                                                           74 (43.8%)                        124.0                     0.74 (0.43 – 1.26)         0.272
     I                                                                                                                                                                1 (0.6%)                           45.0                     6.45 (0.86 – 48.40)        0.069
Metastases
     No                                                                                                                             87                        60 (67.4%)                        118.5                                 Ref
     Yes                                                                                                                                                        29 (32.6%)                         99.0                      1.61 (0.81 – 3.22)         0.172
First discovery of symptoms of disease
     Patient                                                                                                                       5                        151 (68.8%)                      116.0                               Ref.
     Mammography                                                                                                                                   20 (14.2%)                        68.5                      2.15 (0.01- 1.12)          0.083
Health care services used before diagnosis of breast cancer
     Public                                                                                                                        3                        114 (64.8%)                        82.5                                  Ref
     Public and private                                                                                                                              49 (27.8%)                        102.0                      1.88 (1.09-3.23)           0.021
     Private                                                                                                                                                   10 (5.7%)                         125.5                      2.57 (1.00-6.63)           0.049
Public or private health care service used at first medical visit
     Public                                                                                                                       27                        90 (60.4%)                        144.0                                 Ref
     Private                                                                                                                                                  59 (39.6%)                         71.0                       3.52 (2.03-6.12)         <0.001
Type of health care service used at first medical visit
     Diagnostic service                                                                                                 27                        73 (41.5%)                         86.0                                  Ref
     Primary health service                                                                                                                     68 (38.6%)                        165.5                     0.26 (0.13 – 0.49)       <0.001
     Hospital                                                                                                                                                  8 (4.5%)                           71.5                      1.35 (0.53 – 3.45)         0.520
Financing of diagnostic mammography
     Direct private payment                                                                                        13                        78 (47.8%)                        103.0                                 Ref
     Public health system                                                                                                                        74 (45.4%)                        139.0                     0.42 (0.23 – 0.78)       <0.001
     Health insurance                                                                                                                                 7 (4.3%)                           69.0                      2.46 (1.02 – 5.90)         0.040
     Donated by NGO                                                                                                                                  4 (2.5%)                          131.0                     1.40 (0.33 – 5.87)         0.630
Coverage of costs of biopsy
     Public health system                                                                                            15                        73 (45.3%)                        139.0                                 Ref
     Health insurance                                                                                                                                 6 (3.7%)                           87.0                       2.26 (0.67-7.63)           0.190
     Direct private payment                                                                                                                     70 (43.5%)                        102.0                      1.80 (1.01-3.19)           0.045
     Donated by NGO                                                                                                                                 12 (7.5%)                          97.0                       1.86 (0.69-4.98)           0.217
Type of first treatment in the FAP or HNL
     Neoadjuvant chemo                                                                                               -                          97 (55.1%)                        118.0                                 Ref
     Surgery                                                                                                                                                78 (44.3%)                        112.5                      1.09 (0.66-1.81)           0.728
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insurance. All other patients financed these diagnostic services pri-
vately by direct payment, or they were financed by the public SUS.
To identify a model of independent variables, multivariate
analysis was performed (Table 3). In this model the coverage of
costs of diagnostic mammography by the public health system
decreased chance of prompt TTI 2.38-fold (HR=0.42; 95%CI:
0.19-0.90), compared to direct private payment (p=0.025; Table 3).
Furthermore, women who initiated patient flow with a primary
health service had a 2.86-fold (HR=0.35; 95%CI: 0.16-0.76)
decreased chance of prompt TTI compared to those who started
patient flow with a diagnostic service (p=0.008; Table 3).
Time intervals and comparison of delays between
patients in the FAP and HNL 
The median time between the first medical visit and the diag-
nostic result was 56.0 days, and 54 (34.8%) out of 155 patients had
a delay of >90 days (Table 4). The median time between the first
medical visit and hospital admission and between first medical
visit and treatment initiation for 173 and 176 patients, respectively,
was 91.0 and 116.5 days, respectively (Table 4). Of these 173 and
176 patients, 87 (50.3%) and 114 (64.8%) patients had a delay of
>90 days (Table 4). The median time between diagnostic results
and treatment initiation was 54.0 days for 236 patients, and 99
(42.0%) of them delayed >60 days (Table 4).
In general, the time intervals were shorter for patients in the
HNL compared to those in the FAP. The median time between the
first medical visit and the diagnostic result was 136.0 and 52.0
days for patients in the FAP and the HNL, respectively (p<0.050;
Table 4). The median time for patients in the FAP and the HNL
who had a delay of >60 days during the latter time interval was
180.0 and 158.0 days, respectively (p=0.032; Table 4). The median
time between the first medical visit and the treatment initiation was
148.0 and 110.0 days for patients in the FAP and the HNL, respec-
tively (p<0.050; Table 4). The median time between the results of
diagnostic mammography and diagnostic results was 79.0 and 38.5
days for patients in the FAP and the HNL, respectively (p<0.05;
Table 4).
To clarify this difference between the two referral centres,
patients were subdivided into two groups: patients in both referral
centres who financed one or more health services (FAPPRIV and
HNLPPRIV) and patients who performed all diagnostic and medical
exams within the public health system (FAPPUB and HNLPUB),
excluding all those who received help from one of the NGOs. The
analysis indicated that most patients had financed a minimum of
one health service: Between the first medical visit and the initia-
tion of treatment of 128 patients in the HNL, 85 (66.4%) financed
a medical service on their own (HNLPRIV), whereas 43 (33.6%)
received all diagnostic services in the public system (HNLPUB;
Table 4). In the case of the FAP, all 29 patients with available data
for this time interval had financed health services privately (FAP-
PRIV; Table 4). The median time between the first medical visit and
treatment initiation was 172.0, 101.0 and 135.0 days for FAPPRIV,
HNLPRIV, and HNLPUP, respectively (p<0.050; Table 4).
Patients in the FAP and HNL used, on average, 4.49 (s=1.8)
and 3.85 (s=1.4) health services, respectively, from their first med-
ical visit until the initiation of treatment (p>0.050). If only patients
were considered who financed a minimum of one or more diagnos-
tic services, the median value for privately financed diagnostic ser-
vices was 3.0 and 2.0 for patients in the FAP and HNL, respective-
ly (p≥0.050). The mean number of private services used was 3.1
(s=1.6 for FAP patients; s=1.9 for HNL patients) for patients in
both the FAP and the HNL (p=0.993).
Delay of the integrated and outsourced clinic-
histopathological exam in the FAP and HNL
As the clinic-histopathological exam was integrated in the
HNL and outsourced in the FAP hospital to private laboratories, we
asked if there exists a relevant difference in the delay of the clinic-
histopathological exam between the outsourced and integrated sys-
tem. First, the time interval between diagnostic mammography and
the diagnostic result was compared among patients of both referral
centres who used exclusively public services. The median time
between the result of diagnostic mammography and the diagnostic
result of FAPPUB and HNLPUB was 122.0 and 41.0 days, respective-
ly (p≥0.05; Table 4). Next, the delay between diagnostic mammog-
raphy and the diagnostic result was compared among the following
groups of patients, independent of whether they had privately
financed any diagnostic service other than the clinic-histopatho-
logical exam (Table 4). Patients in the FAP who performed the
clinic-histopathological exam outsourced in a private laboratory
and financed it with the public health system (FAPOUTPUP) or those
who financed it privately (FAPOUTPRIV); and all patients who per-
formed the histopathological exam within the HNL, financed by
the public health system (HNLINT). Together, the FAPOUTPUP,
FAPOUTPRIV and HNLINT groups encompassed 60, 77 and 45
patients, respectively (Table 4). The median time between the
results of diagnostic mammography and the diagnostic results for
FAPOUTPUP, FAPOUTPRIV and HNLINT, was 65.0, 29.0 and 53.0 days,
respectively (p<0.050; Table 4).
Time intervals for patients who were supported by one
of the NGOs
We asked if support by NGOs could accelerate patient flow.
Therefore, patients of both referral centres who received support
                            Article
Table 3. Hazard ratios (HRs) and confidence intervals (CIs) are shown for a model of multivariate Cox regression analysis. The HR was
calculated as the likelihood of hospital treatment initiation within 90 days after the first medical consultation.
                                                                                                                           HR* (95%CI)                                                    p#
Financing of diagnostic mammography                                                                                                                                                                                            
      Direct private payment                                                                                                                         Ref.                                                                                 
      Public health system                                                                                                                   0.42 (0.19-0.90)                                                                  0.025
      Health insurance                                                                                                                         2.15 (1.06- 4.36)                                                                 0.033
      Donated by NGO                                                                                                                          0.74 (0.14-3.93)                                                                  0.731
Type of health care service at first medical visit                                                                                                                                                                           
      Diagnostic service                                                                                                                                  Ref.                                                                                 
      Primary health service                                                                                                               0.35 (0.16- 0.76)                                                                 0.008
      Hospital                                                                                                                                         1.60 (0.48- 5.29)                                                                 0.441
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Table 4. Time intervals are shown in days for groups of patients for descriptive and Kaplan-Meier analysis. Numbers and mean and
median values are shown for all patients and those ones with time intervals >90 and >60 days of each group. Numbers, percentages and
mean and median values of Kaplan-Meier analysis refer to patients who delayed >90 days and >60 days for a determined time interval.
The 25th percentile of Kaplan-Meier analysis defined the time (in days) after which 75% of these patients delayed. Diagnostic results
were defined as the date of the result of the clinic- histopathological exam.
All                                                                                                Time interval >90 days
                           N               Mean               75%         Median          p          NDELAY (%)             Mean            25%        Median (95%CI)     p
First medical visit – Diagnostic result
All                               155          128.8 (s=493.3)           136.0                56.0                                  54 (34.8%)          298.8(s=110.6)        260.0            160 (151.6- 168.4)         
FAP                             31          324.8 (s=1082.9)          229.0               136.0          <0.050*        17 (54.8%)            562.8 (348.5)          284.0           180.0 (88.6- 271.4)   0.032^
HNL                           124            79.8 (s=80.9)             107.8                52.0           <0.050*        37 (29.8%)             177.5 (14.0)           183.0          158.0 (139.1- 176.9)  0.032^
FAPPRIV                        25           374.7 (s= 204.5)          260.5               110.0          <0.050*        14 (56.0%)           640.8 (s=423)         334.0           180.0 (29.7- 330.3)    0.118$
HNLPRIV                       75                70.3 (70.3)                93.0                 41.0           <0.050*        19 (25.3%)            172 (s= 5.2)          183.0          160.0 (157.2- 162.8)   0.118$
HNLPUB                       38           114.3 (s=101.6)           142.3               114.3                                 17 (44.7%)          196.1 (s=24.7)        260.0          161.0  (103.2- 218.8)       
NGO                           17             58.0 (s=99.0)              99.0                 28.0            <0.050°         4 (23.5%)            140.0 (s=6.2)         144.0          144.0 (125.3- 162.7)        
Public                         38           114.3 (s=142.3)           142.3                77.5            <0.050°        17 (44.7%)          196.1 (s=24.7)        260.0          161.0 (103.2- 218.8)   0.319$
Private                      100          146.4 (s=139.8)           139.8                48.5            <0.050°        33 (33.0%)         370.9 (s=110.6)       255.0          162.0 (148.5- 168.4)   0.022$
First medical visit - Hospital admission
All                               173         375.5 (s=3238.4)          168.0                91.0                                  87 (50.3%)         704.5 (s=488.4)       249.0          167.0 (147.7- 186.3)        
FAP                             35         1345.2 (s=7085.3)         255.0               142.0          <0.050*        25 (71.4%)        1924.4 (s= 697.9)      333.0          190.0 (170.4- 209.6)  0.055^
HNL                           138         120.69 (s=170.6)          151.5                79.0           <0.050*        62 (44.9%)          212.7 (s= 27.7)        269.0          156.0 (125.1- 186.9)  0.055^
First medical visit - Treatment initiation 
All                               176         396.7 (s=3211.9)          193.5               116.5                               114  (64.8%)       583.2 (s= 373.2)       248.0          167.0 (144.0- 190.0)        
FAP                             36           1319.7 (s=148)           217.5               148.0          <0.050*        28 (77.8%)       1742.3 (s= 1517.6)     314.0          186.0 (134.1- 237.9)   0.094$
HNL                           140           151 (s=166.7)            184.0               110.0          <0.050*        86 (61.4%)          205.8 (s= 20.5)        227.0          162.0 (134.7- 189.3)   0.094$
FAPPRIV                        29         1659.1 (s=7896.8)         294.5               172.0           <0.050°        22 (75.9%)       2170.6 (s= 1930.7)     341.0          186.0 (155.0- 217.0)   0.173$
HNLPRIV                       85           146.0 (s=195.6)           173.0               101.0           <0.050°        47 (50.3%)          218.3 (s= 35.0)        252.0          165.0 (130.3- 199.7)   0.173$
HNLPUB                       43          172.16 (s=114.5)          222.0               135.0           <0.050°        33 (76.7%)          207.8 (s= 18.7)        248.0            179 (137.4- 220.6)    0.173$
NGO                           18           105.17 (s=55.0)           141.3               101.5          <0.050*        12 (66.7%)          134.6 (s= 12.2)        148.0           113.0 (85.8- 140.2)    0.006$
PUBLIC                      44          168.27 (s=116.1)          221.5               132.0          <0.050*        33 (75.0%)          207.8 (s= 18.7)        248.0          179.0 (137.4- 220.6)   0.006$
PRIVATE                   114         530.9 (s=3989.8)          192.5               112.5                                 69 (60.5%)         840.8 (s= 616.3)       272.0          173.0 (152.1- 193.9)   0.006$
                                                All                                                                                                       Time interval >60 days
Result of diagnostic mammography - Diagnostic result
All                               219          101.6 (s= 65.5)           121.3                 45                                   91 (41.6%)          209.3 (s= 22.6)        274.0            134 (109.9- 158.2)         
FAP                             71           153.5 (s=239.9)           160.0                79.0           <0.050*        44 (62.0%)          246.3 (s= 42.0)        288.0          154.0 (120.4- 187.6)   0.135$
HNL                           148           77.5 (s=106.9)             85.0                 38.5           <0.050*        47 (31.8%)          174.7 (s= 18.2)        252.0           127.0 (112.2-141.8)   0.135$
FAPPUB                         11           185.7 (s=176.9)           311.0               122.0           ≥0.050*         8 (72.7%)           247.5 (s= 59.9)        311.0          125.0 (0.000- 355.1)   0.580$
HNLPUB                       45            99.8 (s=130.8)            127.5                41.0            ≥0.050*        19 (42.2%)          205.3 (s= 33.5)        301.0           134.0 (0.000-286.2)   0.580$
FAPOUTPUP                    60           149.5 (s=247.9)           154.8                65.0            <0.050°        32 (53.3%)             255.8 (53.6)           288.0           149.0 (107.4- 190.6    0.227$
FAPOUTPRIV                   77              71 (s=103.9)              77.5                 29.0            <0.050°        25 (22.5%)          171.2 (s= 27.0)        188.0           126.0 (73.8- 178.2)    0.227$
HNLINT                        45                95.1 (97.5)               127.5                53.0            <0.050°        22 (48.9%)          169.2 (s= 19.6)        264.0           127.0 (97.6- 156.4)    0.227$
Result of diagnostic mammography - Hospital admission
All                               229         132.7 (s= 167.8)          164.0                79.0                                 142 (62.0%)         194.3 (s= 15.7)        224.0          141.0 (122.5- 159.6)        
FAPPRIV                        48           204.2 (s= 255.6)          235.8               119.0           <0.050#        39 (81.3%)          282.5 (s= 54.4)        314.0          164.0 (139.2- 188.8)   0.028$
HNLPRIV                       91           123.8 (s= 128.4)          164.0                74.0            <0.050#        78 (85.7%)          176.4 (s= 17.7)        225.0           125.0 (77.7- 172.3)    0.028$
FAPPUB                         14             89.6 (s= 49.1)            141.5                76.0            ≥0.050*        12 (85.7%)          117.0 (s= 12.9)        146.0           135.0 (50.3- 219.7)    0.136$
HNLPUB                       51           103.3 (s= 106.9)          132.0                74.0            ≥0.050*        44 (86.3%)          164.0 (s= 21.1)        198.0          118.0 (95.18- 140.8)   0.136$
Result of diagnostic mammography - Treatment initiation
All                               241         153.1 (s= 163.2)          179.0               111.0                                191 (79.3%)         182.3 (s= 12.4)         94.0           131.0 (119.9- 142.1)        
Diagnostic result - Treatment initiation
All                               236          62.39 (s= 47.9)            79.8                 54.0                                  99 (42.0%)           101.3 (s= 5.0)         113.0            86.0 (79.04- 93.0)          
NGO                           30             53.2 (s= 24.9)             66.8                 56.5            ≥0.050°        14 (46.7%)            76.6 (s= 4.5)           88.0              69.0 (61.7- 76.3)      0.004$
PUBLIC                      61             62.8 (s= 42.1)             79.0                 56.0            ≥0.050°        23 (37.7%)          102.0 (s= 8.6-)        151.0             86.0 (76.7- 95.3)      0.004$
PRIVATE                   145            64.1 (s= 53.5)             85.0                 54.0            ≥0.050°        62 (42.8%)           106.7 (s= 7.2)         116.0            93.0 (82.4- 103.6)     0.004$
ALL, all patients; FAP, all patients from the FAP; HNL, all patients from HNL; NGO, patients who received help from one of the NGOs; PUBLIC, FAPPUB, HNLPUB, all patients and patients of the FAP and the HNL who per-
formed all diagnostic and other medical exams within the public health service system; patients who received help from one of the NGOs were excluded from the analysis; PRIVATE, FAPPRIV, HNLPRIV, all patients and
patients of the FAP and the HNL who privately financed a minimum of one diagnostic or other medical service. Patients who received help from one of the NGOs were excluded from this analysis; FAPOUTPUP, patients
of the FAP who performed the clinical histopathological exam outsourced in a private laboratory financed by the public health system; FAPOUTPRIV, patients of the FAP who privately financed the clinical histopathological
exam that was performed in a private laboratory; HNLINT, patients who performed the clinical histopathological exam in the HNL, financed by the public health system; s=standard deviation; p-values for analysis of time
intervals of all patients: *Mann-Whitney (U-Test); °Kruskal-Wallis test; #Kolmogorov-Smirnov test; for Kaplan-Meier analysis (Time interval >60 days and >90 days): ^Breslow (Generalized Wilcoxon)-test; $Log Rank
(Mantel-Cox)-test.
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from NGOs  were compared with those who had privately financed
one or more diagnostic or medical exams (PRIVATE) and those
who exclusively performed these exams within the public health
system (PUBLIC; Table 4). Patients who were supported by one of
the NGOs and those who used exclusively public diagnostic ser-
vices without the help of NGOs had a median time of 28.0 and 77.5
days, respectively, between the first presentation and the diagnos-
tic result (p<0.05; Table 4). The median time of patients who
delayed >60 days during the latter time interval was 144.0 days for
the NGO and 162.0 days for the PRIVATE patient groups
(p=0.022; Table 4). The median time between the first medical
visit and the initiation of treatment for the NGO, PUBLIC and
PRIVATE groups was 101.05, 132.0 and 112.5 days, respectively
(p<0.05; Table 4). The median time for patients with a delay of >60
days for the latter time interval was 113.0, 179.0 and 173.0 days
for the NGO, PUBLIC and PRIVATE patient groups, respectively
(p=0.006; Table 4). For the time interval between the results of
diagnostic mammography and treatment initiation, the median
time for patients with a delay of >60 days was 69.0, 86.0 and 93.0
days for the NGO, PUBLIC and PRIVATE patient groups, respec-
tively (p=0.004; Table 4). Other time intervals were not signifi-
cantly different but were generally shorter for patients who
received support from one of the NGOs.
Discussion
To the best of our knowledge this is the first Brazilian study
that compared delay of cancer treatment between two public refer-
ral centres with integrated and outsourced diagnostic services.
Data indicated that publicly financed diagnostic mammography
and clinical- histopathological exam are performed faster in the
integrated system of the HNL referral centre, compared to the out-
sourced system of the FAP hospital. There is an ongoing debate in
Brazil regarding the privatization of the public health care
services.27 The present study is a contribution to this debate.
Variables that were associated with TTI
Cox regression analysis indicated that prolonged TTI was gen-
erally associated with the use of public health services. Women
who used principally public health services before disease discov-
ery and at the beginning of patient flow had an increased chance of
delay of >90 days between the first medical visit and the initiation
of treatment. This finding was also underlined by the observation
that women who covered the costs of diagnostic mammography
and biopsy on their own had a decreased risk of delay compared to
women who used public health services for these exams. In most
cases, those women who used a diagnostic service at the beginning
of patient flow financed this service on their own. Consequently,
the usage of a diagnostic service at the beginning of patient flow
also reduced the risk of delay compared to the usage of a public
health service. Furthermore, patients who started treatment in a
private hospital and continued it in one of both public referral cen-
tres also had a decreased delay.
Time intervals and prolonged TTI of all patients
For patients in both referral centres combined, the median time
interval between the first medical visit and diagnostic results was
56.0 days. This finding is in contrast to those of earlier studies per-
formed in the states of Rio de Janeiro and Minas Gerais that report-
ed median and mean waiting times of 6.5 months and >6 months,
respectively, between the first medical visit and diagnostic confir-
mation.16,18 Similar, a study performed in Malaysia revealed a
median time interval of 5.5 months for the time between the first
medical visit and diagnosis.31 The present value of 56.0 days was
within the median time span ranging from 0.9 to 5.0 months for the
time interval between the first medical visit and the completed
diagnosis of nine studies from low- and middle-income coun-
tries.32 The present results indicated a delay of >90 days between
the first medical visit and the diagnostic results for 34.8% of the
patients. In contrast, a recent study performed in Rio de Janeiro
revealed a delay of 68.8% among 526 patients ≥90 days between
the first medical visit and the diagnosis.33 Similar to the present
results, a study performed in Thailand reported a delay of >90 days
for 42% of all patients for this time interval.34 The median time
between the first medical visit and hospital admission and treat-
ment initiation was 91.0 and 116.5 days, respectively. This is in
contrast to a recent Portuguese study of 282 patients who had a
shorter median delay of 44 days between the first diagnosis and
treatment initiation.35
The median time between the result of diagnosis and treatment
initiation was 54.0 days for 236 patients of both referral centres.
Lower median values for this time interval of 0.6 to 1.2 months
were reported in eight studies from low- and middle-income coun-
tries.32 A recent study performed in the USA revealed median val-
ues of 62.0 and 35.5 days for breast cancer patients of African and
Caucasian ancestry.36 Similar to the present results, in a recent
study performed in the state of Ceará, north-eastern Brazil, the
median time between diagnosis and hospital admission was 39 and
71.5 days for patients referred by the private and public health sys-
tem, respectively.25
Different time intervals for public and privately
financed health services 
Consistent with the results of Cox regression analysis, the
comparison of time intervals among different patient groups indi-
cated a faster patient flow for women who financed a minimum of
one health care service on their own. A prolonged TTI associated
with a lack of financial resources was also perceived in recent stud-
ies of Mexican breast cancer patients.7,37 Previous Brazilian stud-
ies reported delays in the public health care system compared to
privately financed health care.15,16,19,20 Studies performed in the
states of Minas Gerais and in Rio de Janeiro also suggested that the
usage of public versus private health services was associated with
an advanced stage of disease and a decreased chance of five-year
survival.16,21 In a study that included data from 56,094 women in
various Brazilian regions, the authors reported increased delays
with respect to the time between diagnosis and treatment initiation
for public referrals compared to private one.33 Long waiting times
for specialized medical consultations and diagnostic exams were
among the main problems in cancer treatment by public health ser-
vices.25,38 These long waiting times can often be the result of a lack
of specialized services: waiting times of up to 30 days for special-
ized services after the detection of the first symptoms were report-
ed.23 Furthermore, guidelines for referrals or requests for sub-
sidiary exams by health professionals are often missing.25,38
Different time intervals among patients in both referral
centres
The results indicated remarkable differences in the delays
among breast cancer patients in two referral hospitals in urban cen-
tres within the same state, located approximately 120 km from
each other. Time intervals were generally shorter for patients in the
HNL in João Pessoa than for patients in the FAP in Campina
Grande.
The comparison of patients who used exclusively public ser-









vices indicated that the chance of prompt TTI was increased
among women in the HNL compared to those in the FAP.
Furthermore, the patients who performed the clinic-histopatholog-
ical exam within the public health service system of the HNL had
a significantly decreased delay compared to patients in the FAP
who also performed it within the public health service system. This
finding indicated that the integrated public diagnostic service of
the HNL was indeed faster than the outsourced service of the FAP.
In the latter case, oncologists of the FAP had to communicate with
the staff of private laboratories, whereas in the HNL, the clinic-
histopathological exam was directly performed in the pathological
sector of the hospital.
Differences in delays between patients of both referral centres
were also obvious for patient groups who used one or more pri-
vately financed health services. These differences may be attribut-
ed to two main explanations. First, in the case of the patients in the
HNL, which is in the capital (João Pessoa), services could be more
concentrated, such that single health care providers could offer
several diagnostic services. Previous studies also found associa-
tions between diagnostic delay and an increased number of health
care providers used before admission to a specialized health care
centre.6,37 On the one hand, this argument was supported by the
fact that patients in the FAP generally used more health care
providers on average than those in the HNL. On the other hand, the
mean number of privately financed services was nearly identical
between both groups of patients. Second, waiting times could be
longer in Campina Grande than in João Pessoa due to a lower num-
ber of private health care providers. The increased number of
health care providers in the capital compared to in Campina
Grande could cause shorter waiting times for exams and corre-
sponding results.
NGOs accelerated patient flow
The present data indicated that the work of the three NGOs
accelerated patient flow. The median and mean time intervals
between the first medical visit and diagnostic results and between
the first medical visit and treatment initiation were significantly
shorter for patients who received support from the NGOs. As the
NGOs paid for biopsies and diagnostic mammograms, this result
indicated that the delay observed was primarily a diagnostic delay
and that the work of the NGOs reduced it. Members of the NGOs
also communicated with oncologists within both referral centres,
and the time between the diagnostic result and treatment initiation
was shorter for patients who were supported by the NGOs.
Therefore, it is plausible that patients who were supported by one
of the NGOs also obtained treatment earlier because of better com-
munication mediated by the NGOs. The authors of a previous
Brazilian study that focused on the time interval between screening
mammography and the treatment initiation of patients in São Paulo
identified the absence of coordination of patient flow and social
assistance for patients as organizational problems and principal
reasons for delays.12
Method limitations
The most severe limitation of the present study was the small
amount of data. The small numbers increased uncertainty of
patient group associated time delays. This issue also hindered the
resolution of detailed differences among patients in the FAP and
HNL who exclusively used public health care services. Low reso-
lution was further aggravated by missing dates of diagnostic health
services, thus reducing the amount of available data for the analy-
sis of each defined time interval. The latter problem was due to the
fact that medical records were incomplete and the patient data of
both referral centres were not digitalized. Errors may have
occurred during the registration of these data in the pathological
reports. A further source of error may be attributed to recall bias
among the interviewed women about the dates and types of health
services. Recall bias may also have been reinforced by the
chemotherapeutic treatment of patients. The recruitment of
patients was stochastic, but the possibility of a selection bias can-
not be eliminated.
The study did not determine in detail why prolonged TTI was
less pronounced for patients who used private health care services
than for those who used only public services. The performance of
privately financed diagnostic services obviously resulted in a
remarkable difference in prolonged TTI among patients in the FAP
and HNL. The present data did not include information about the
specific private health care provider that was used for a determined
diagnostic process. Therefore, it was not possible to attribute
longer waiting times for a diagnostic service to specific private
health care services, and the real cause of different delays among
patients in the FAP and HNL who financed diagnostic services pri-
vately remained unclear.
Conclusions
The present data indicated that patients who used public diag-
nostic services had prolonged TTI compared to those who financed
these services privately. The TTI was shorter for patients who used
private health care services before the diagnosis of disease and at
first medical visit and who financed privately diagnostic mammog-
raphy and biopsy. In general, delay was increased among patients
in the FAP compared to those in the HNL in the capital João
Pessoa. The results indicated that the integrated clinical
histopathological exam in the HNL accelerated patient flow com-
pared to the outsourced exam in the FAP. Furthermore, the differ-
ence in the delay among patients of both referral centres was also
caused by distinct patient flow within the privately financed health
sector. The results clearly indicated that the NGOs’ donation of
biopsies and diagnostic mammograms and strong communication
skills accelerated patient flow.
The present data indicated that there could be a reduction in
TTI via the concentration of diagnostic services in the state of
Paraíba. The design of future studies should further address the
question of whether the concentration of diagnostic services in
public referral centres and private laboratories can reduce TTI
among breast cancer patients. Furthermore, it should be elucidated
whether an increased number of private health care providers can
help to reduce the waiting time for diagnostic services.
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